Singular Genomics Completes Acquisition by Deerfield Management

Singular Genomics Systems, Inc., a key player in the next-generation sequencing (NGS) and spatial multiomics technologies sector, has announced the completion of its acquisition by an affiliate of Deerfield Management Company, highlighting a significant shift in its operational strategy. The acquisition deal was disclosed to have been formalized on December 23, 2024, where Deerfield Management agreed to acquire outstanding common stock of Singular Genomics at a cash value of $20.00 per share. Following all required procedures, including shareholder approval obtained on February 19, 2025, the transaction successfully concluded. As part of this transition, Singular Genomics is now a private firm, endorsing its aim to accelerate its scientific and commercial objectives with improved operational flexibility outside the public market's pressures—its stocks have been delisted from Nasdaq. Key leadership changes include the appointment of Josh Stahl as CEO, with Jason Myers and co-founder Drew Spaventa playing significant roles on the board. Deerfield Management has expressed optimism in guiding Singular Genomics in achieving its mission of enabling advanced genomics solutions for researchers and clinicians. The transaction was advised by financial advisors TD Securities and Houlihan Lokey, and legal advisory support from several firms including Gunderson Dettmer, LLP and Richards, Layton & Finger, P.A. for Singular, and Katten Muchin Rosenman LLP for Deerfield.